Viral Vectors and Plasmid DNA Manufacturing Market, 2026 - Research and Markets

DUBLIN, Feb 15, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026" report to their offering.

The "Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026" report provides an extensive study of the rapidly growing market of gene therapy vectors, with a special focus on lentivirus, AAV, adenovirus, retrovirus and plasmid DNA.

Gene therapies require a viral or non-viral vector to efficiently transfer the therapeutic gene into targets cells. It is well known that the gene therapy market is characterized by a robust pipeline of drugs targeting several therapeutic indications. The pipeline is witnessing continuous progression that has further led to an upward surge in demand for gene delivery tools, including both viral and non-viral vectors.

Several players, including pharmaceutical companies, research institutes, contract manufacturing organizations and non-profit organizations, are playing a critical role in the development and production of these vectors. Led by technological advancements, these organizations have developed and introduced proprietary platforms to overcome the challenges posed by conventional production technologies and have also made heavy investments in the expansion of their existing capabilities for vector production.

During the course of our study, we identified over 140 organizations that are actively involved in the production of viral vectors and plasmid DNA.

In addition to other elements, the study provides information on:

- The current status of the market with respect to key players along with information on the location of their manufacturing facilities, scale of production, type of vectors manufactured, purpose of production (fulfilling in-house requirement/as a contract service provider) and the type of organization (industry/academia).

- Most active regions in terms of vector manufacturing; the report contains schematic representations of world maps that clearly indicate the locations of global vector manufacturing hubs.

- Elaborate profiles of key players that have commercial scale production capabilities for viral vector/plasmid DNA; each profile covers an overview of the company, its financial performance, information on its manufacturing facilities, vector manufacturing technology, recent investments, expansions and collaborations.

- A discussion on the key enablers of the market and challenges associated with the vector production process.

- Potential future growth of the vector manufacturing market segmented by the type of vector and phase of development. For the purposes of our analysis, we took into consideration several parameters that are likely to impact the growth of this market over the next decade; these include the likely increase in the number of clinical studies, increase in the patient population, existing price variations among different vector types, estimated dosage frequency and the anticipated success of commercial gene therapy products.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 100 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth.Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain.

The report features detailed transcripts of interviews held with Alain Lamproye (President of Biopharma Business Unit, Novasep), Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital), Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing), Joost van den Berg (Director, Amsterdam BioTherapeutics Unit), Nicole Faust (Chief Scientific Officer, Cevec) and Semyon Rubinchik (Scientific Director, ACGT).

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Viral Vectors

6. Plasmid DNA

7. Opportunity Analysis

8. Survey Analysis

9. Conclusion

10. Interview Transcripts

11. Appendix 1: Tabulated Data

12. Appendix 2: List of Companies and Organizations

• 4D Molecular Therapeutics
• ACGT
• Advanced BioScience Laboratories
• Advanced Biotherapeutics Consulting
• Aldevron
• Allele Biotechnology
• Althea Technologies
• Ampersand Capital Partners
• AMSBIO
• Amsterdam BioTherapeutics Unit
• Applied Biological Materials
• Applied Genetic Technologies Corporation
• Applied Viromics
• ARCO Design/Build
• Areta International
• Asklepios BioPharmaceutical
• Atlantic Bio GMP
• Avalanche Biotechnologies
• Batavia Biosciences
• Beckman Research Institute
• Benitec Biopharma
• BioCancell
• Biogen Idec
• Biomay
• Biomiga
• BioReliance/SAFC
• Biotec Services International
• BioTie Therapies
• BioVex (Amgen subsidiary)
• Biovian
• Blue Sky BioServices
• bluebird bio
• BMS
• Boehringer Ingelheim BioXcellence
• Brammer Bio
• Brookside Capital
• Cancer Research UK (Biotherapeutics Development Unit)
• Carnegie Institution of Washington
• Cell and Gene Therapy Catapult
• Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
• Celladon
• Center for Biomedicine & Genetics, City of Hope
• Center for Cell & Gene Therapy, Baylor College of Medicine
• Center for Cell and Gene Processing, Takara Bio
• Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia
• Centre for Process Innovation
• CEPiA (Industrial Affairs Division of Sanofi )
• CEVEC Pharmaceuticals
• Children's GMP/GMP facility St. Jude Children's Research Hospital
• Cincinnati Children's Hospital Medical Center
• Clinical Biotechnology Centre, NHS Blood and Transplant
• Cobra Biologics
• Core Facility for Therapeutic Vectors, Institute of Medical Science Research Hospital
• Cranfield University
• CRB
• Creative Biogene
• Creed Commercial Development
• Crucell
• CureLab
• Deerfield Management Company
• DSM Biologics
• Epeius Biotechnologies
• EUFETS (BioNTech)
• Eurofins Genomics
• Eurogentec
• Finnish Bioindustries FIB
• Finnish Fair Foundation
• FinVector
• Fondazione Telethon
• Fraunhofer Institute for Toxicology and Experimental Medicine
• Frederik Paulsen Foundation
• FUJIFILM Diosynth Biotechnologies
• GEG Tech
• Genable Technologies
• Gene and Cell Therapy Lab, Institute of Translational Health Sciences
• Gene Medicine Japan
• Gene Transfer Vector Core (Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary)
• Gene Transfer, Targeting and Therapeutics Core, Salk Institute for Biological Studies
• Gene Vector and Virus Core, Stanford Medicine
• GeneCure Biotechnologies
• GeneDetect
• GeneImmune Biotechnology
• Genethon (Genethon BioProd)
• GENEWIZ
• GenIbet Biopharmaceuticals
• Génopoïétic
• GenScript
• GenVec
• Genzyme
• GSEx, The Robinson Research Institute, University of Adelaide
• GSK
• Guy's and St Thomas' NHS Foundation Trust
• Hercules Technology Growth Capital
• Hope Center Viral Vectors Core, Washington University School of Medicine
• Human Gene and Cell Therapy Center, Akdeniz University
• Human Stem Cells Institute
• ID Pharma
• Immune Design
• Immune Technology
• Innovate UK
• InvivoGen
• Karolinska University Hospital
• King's College London, Rayne Cell Therapy Suite
• Kobe Biomedical Accelerator
• Lentigen Technology
• Lonza
• Luminous BioSciences
• Massachusetts Eye and Ear
• Massachusetts Life Science Center
• MassBiologics
• Merck
• Meridian Life Science
• MGH Vector Core (Massachusetts General Hospital Neuroscience Center)
• Microbix Biosystems/McMaster University
• Miltenyi Biotec
• Mitsubishi Corporation
• Molecular Diagnostic Services
• MolMed
• Nantes Gene Therapy Institute
• National Institute of Neurodegenerative Disorders and Stroke Center Core
• Nature Technology Corporation
• Netherlands Cancer Institute
• NeuroCure
• Novartis
• Novasep
• Oberland Capital
• Ocular Gene Therapy Core, National Eye Institute
• Okairos (GSK subsidiary)
• Omnia Biologics
• Ospedale San Raffaele
• OXB Solutions
• Oxford BioMedica
• Oxford Genetics
• PacificGMP (a part of Abzena Group)
• Paragon Bioservices
• Penn Vector Core, University of Pennsylvania
• Pfizer
• Pinchal
• Plasmid Factory
• Puresyn
• RecipharmCobra Biologics
• REGENXBIO
• Renova Therapeutics
• Research Center for Hematology of the Russian Ministry of Healthcare
• Richter-Helm
• Rimedion
• Rock Springs Capital
• SAB Technology
• San Raffaele Telethon Institute for Gene Therapy
• Sanofi
• Sanofi-Pasteur
• Scancell
• Shanghai Sunway Biotech
• Shenzhen SiBiono Gene-Tech
• SiBionoGeneTech
• SignaGen Laboratories
• Sino Biological
• Sirion Biotech
• Sofinnova Ventures
• Southern Research - Bioanalytical Sciences Department
• Spark Therapeutics
• Stanford University (Human Gene Therapy)
• Stevenage Borough Council
• Synpromics
• System Biosciences
• T. Rowe Price Associates
• Tecrea
• Telethon Foundation
• The Goldyne Savad Institute of Gene Therapy, Hadassah Medical Organization
• The Hong Kong Institute of Biotechnology
• The Lentiviral Laboratory, USC School of Pharmacy
• The Vector Core, University of North Carolina
• The Wellcome Trust/BRC Clinical Research Facility and Cell Therapy Unit, King's College London
• THERAVECTYS
• Thermo Fisher Scientific
• Touchlight Genetics
• Transgene
• UAB Vector Production Facility
• UK Technology Strategy Board
• uniQure
• Unit Biotech & ATMP's, University Medical Center Groningen
• University of Iowa Research Foundation
• University of Massachusetts Medical School
• University of Minnesota
• University of North Carolina
• University of Oxford Clinical BioManufacturing Facility
• University of Pennsylvania
• Vaccibody
• Valneva
• Vectalys
• Vector Biolabs
• Vector Core/GMP Core, Belfer Gene Therapy Core Facility, Cornell University
• Vector Core/GMP Facility, UC Davis
• Vector Core Lab/Human Applications Lab, Powell Gene Therapy Center, University of Florida
• Vector Core of Gene Therapy Laboratory of Nantes
• Vector Core, Harvard Gene Therapy Initiative
• Vector Core, Telethon Institute of Genetics and Medicine
• Vector Core, University of Michigan Medical Center
• Vector Production Facility, Indiana University
• Vecura
• VGXI
• Vibalogics
• Vical
• ViGene Biosciences
• Viral Gene Transfer Core, MIT
• Viral Vector Core/Clinical Manufacturing Facility, Nationwide Children's Hospital
• Viral Vector Core, Duke University
• Viral Vector Core, Sanford Burnham Prebys Medical Discovery Institute
• Viral Vector Core, University of Massachusetts Medical School
• Viral Vector Core,University of Iowa Carver College of Medicine
• Viral Vector Production Laboratory, Mayo Clinic Cancer Center
• Virovek
• VIVEbioTECH
• Voyager Therapeutics
• Waisman Biomanufacturing
• Wellington Management Company
• WH Partnership
• Wolfson Gene Therapy Unit, University College of London
• WuXi AppTec
• ZambonGroup
• Zhengyang Gene Technology

For more information about this report visit http://www.researchandmarkets.com/research/twvddp/viral_vectors_and

Media Contact:

Laura Wood, Senior Manager
[email protected] 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com